Born on Jan. 1, Alan Morris is used to sharing a birthday with the New Year. Now the lymphoma patient also has a special day marking what he considers his rebirth — and a harbinger of hope. On Jan. 24, Morris, 58, became the first Dana-Farber Brigham Cancer Center patient to receive outpatient CAR T-cell … Read more
A cytokine storm is a severe immune system reaction to infection, autoimmune condition, or other disease, including some cancers. It occurs when the body produces extremely high levels of certain cytokines, which are proteins that raise or lower immune activity. The deluge of cytokines into the bloodstream can result in severe inflammation across multiple bodily … Read more
As head of a family that includes seven children and 12 grandchildren, Susan Voigt says she is used to putting other people first. When it comes to trailblazing multiple myeloma treatment, however, she is proudly out in front. A longtime Vermont resident, Voigt, 69, was the first person from her state to receive CAR T-cell … Read more
Ken Karnes enjoys his whirlwind of a life. If he’s not traveling to Europe or Asia for his high-tech job — pandemics permitting — he and his wife Mary are busy keeping up with their four daughters, two sons-in-law, and three grandchildren. Road races are also on the 60-year-old’s agenda, with an eye toward his … Read more
Due to COVID-19, Ava Girolimetti doesn’t know if she will be starting middle school this September in a classroom, on a computer screen, or a combination of both. But thanks to CAR T-cell therapy for acute lymphoblastic leukemia (ALL), she plans to be there cancer-free. The rising sixth grader can make this claim as one … Read more
Two years ago, with a new wife and large extended family on his mind, Jose Dos Anjos told caregivers he would do anything to help himself and others facing the aggressive, life-threatening blood cancer known as mantle cell lymphoma (MCL). Now, thanks in part to this willingness, he and fellow MCL patients have renewed hope … Read more
Mantle cell lymphoma is a rare, often aggressive form of non-Hodgkin lymphoma (NHL), a cancer that involves white blood cells known as lymphocytes, which help protect the body from disease. It is named for its origins in the mantle zone — a ring of cells within the lymph nodes where B cells (a type of … Read more
Since it was approved by the U.S. Food and Drug Administration (FDA) in the fall of 2017, a form of the powerful and promising therapy known as CAR T-cell therapy has been used to treat certain young patients with B-cell acute lymphoblastic leukemia (ALL) who have relapsed or didn’t respond to standard regimens. Today, researchers … Read more
Jerry Jalbert is always up for new adventures. He did not expect that non-Hodgkin lymphoma (NHL) would be one of them, but with the help of CAR T-cell therapy that keeps his cancer at bay, the 73-year-old professional photographer-turned-baker-turned-forest checkpoint operator is continuing to enjoy life’s many journeys alongside his wife, Ethel. “We are not … Read more
In May 2018, Tyler Goodwin underwent CAR T-cell therapy for follicular non-Hodgkin lymphoma (NHL). While he was having preparatory chemotherapy for the procedure, a surprise visitor to his hospital bedside provided a powerful reminder of why this promising new cancer treatment was so important to him. “It was my daughter Theresa, all made up for … Read more
After undergoing a promising new treatment for acute lymphoblastic leukemia (ALL), Cole Malone is back to doing what he loves: playing on a flag football team with his twin brother, Michael. Cole and Michael Malone, who are 14, already know plenty about teamwork. Michael served as a perfect-match donor when Cole underwent a stem cell … Read more
In early 2018, Sandra Linberg received an infusion of CAR T cells only a few months after the therapy was approved for treating her type of cancer. After only a month, her lymphoma had completely disappeared – she was in a complete remission. “Those little warrior cells took care of it,” declared Linberg, who has continued … Read more
A year ago, Kelly Lamphere’s multiple myeloma was not responding to treatment, and her legs were so weakened by the cancer in her bones that she relied on a wheelchair and a walker. Today, because of CAR T-cell therapy, Lamphere’s disease is under control—and she can walk unaided again.
CAR T-cell therapy—a form of immunotherapy that uses genetically engineered T cells to intensify the immune system’s response to cancer—represents one of the biggest advances against cancer in recent years.
CAR T-cell therapy uses specially altered T cells — which are part of the body’s immune system — to fight cancer.
Boston-based researchers hope to optimize CAR T-cell therapies to target DIPG, aggressive and difficult-to-treat brain tumors, and other tough-to-treat cancers.
Gene therapy is a way of treating or preventing disease by altering the genetic instructions within an individual’s cells.
CAR T-cell therapy is a form of immunotherapy that uses specially modified T cells – part of the body’s defense system against disease – to attack cancer. As of March 2021, CAR T-cell therapy has been approved by the U.S. Food and Drug Administration as standard therapy for: Some adult patients with aggressive non-Hodgkin lymphoma that has … Read more
“Living” drugs consist of fully functional cells that have been selected and often modified to treat specific diseases, such as cancer. CAR T-cell therapy and therapeutic vaccines fall into this category.